PLoS ONE 2015-01-01

Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment.

Jen-Hao Yeh, Chao-Hung Hung, Jing-Houng Wang, Chien-Hung Chen, Kwong-Ming Kee, Chung-Mou Kuo, Yi-Hao Yen, Yu-Fan Cheng, Yen-Yang Chen, Hsuan-Chi Hsu, Sheng-Nan Lu

Index: PLoS ONE 10 , e0144893, (2015)

Full Text: HTML

Abstract

Current hepatocellular carcinoma (HCC) staging systems only use baseline characteristics to predict outcome. We aimed to explore modifiable factors of the prognosis in HCC cases had undergone non-surgical treatment.All HCC cases in Kaohsiung Chang Gung Memorial hospital in southern Taiwan from 2002 to 2012 must met all below criteria: (1) met international diagnostic guidelines, (2) underwent the initial treatments in our hospital (3) treated by non-surgical treatment modalities and (4) survived more than two years, with follow-up time longer than five years.A total 698 patients were enrolled: 451 (24.6%, group A) survivied between 2 to 5 years, and 247 (13.5%, group B) had survived > 5 years. Aside from liver function reserve and BCLC stages, four interventional factors: initial treatment modality, outcomes of 1st or 2nd treatment, and anti-viral therapy to chronic viral hepatitis were associated with prognosis. After propensity score matching, multiple logistic regression of 223 well-matched pairs showed that recurrence within one year after 1st treatment (OR: 2.17, 95% CI: 1.35-3.48), incomplete 2nd treatment (2.01, 1.27-3.17) and absence of anti-viral agents (1.68, 1.09-2.59) were independent poor prognostic factors.Complete treatment and anti-viral agents to chronic hepatitis were both independent modifiable prognostic factors of HCC patients had undergone non-surgical treatment. Based on these findings, timely treatment to achieve maximal locoregional control and anti-viral treatment should be provided as possible.


Related Compounds

Related Articles:

Formation of covalently closed circular DNA in Hep38.7-Tet cells, a tetracycline inducible hepatitis B virus expression cell line.

2014-09-26

[Biochem. Biophys. Res. Commun. 452(3) , 315-21, (2014)]

Influence of the basal core promoter and precore mutation on replication of hepatitis B virus and antiviral susceptibility of different genotypes.

2015-04-01

[J. Med. Virol. 87(4) , 601-8, (2015)]

Decreased liver distribution of entecavir is related to down-regulation of Oat2/Oct1 and up-regulation of Mrp1/2/3/5 in rat liver fibrosis.

2015-04-25

[Eur. J. Pharm. Sci. 71 , 73-9, (2015)]

Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China.

2015-03-01

[Clin. Drug Investig. 35(3) , 197-209, (2015)]

Hepatitis B Virus and DNA Stimulation Trigger a Rapid Innate Immune Response through NF-κB.

2016-07-15

[J. Immunol. 197 , 630-43, (2016)]

More Articles...